Market cap MXN 14.4BNext earnings 2026-10-21Updated Oct 23, 2026
Our verdict
Trades 26% below our fair value
Price
MXN 15.33
Model fair valueConfidence: good
MXN 20.64
Model range
MXN 5.13 to MXN 39.35
Fair value MXN 20.64
Price MXN 15.33
4 models fit Genomma Lab Internacional and they partly agree: 2 of 4 land within 15% of the average.
Two or more of our models back this value.
Large discount(i)Bronze50
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, Graham number, and Dividend discount.
ACCE opinionGenomma Lab Internacional (LABB.MX)
Fair value (4 models)
MXN 20.64
ACCE price target
MXN 14.78
Rating
Undervalued
Horizon
12 months
Fair value published on 23 Oct 2026, 12:04 CEST; previously MXN 24.32 since 21 Oct 2026, 11:06 CEST.
ACCE price target published on 17 Oct 2026, 00:00 CEST.
Rating published on 21 Oct 2026, 11:06 CEST.
Price used: MXN 15.33 at the close on 23 Oct 2026, 23:00 CEST.
Models: Discounted cash flow, EV/EBITDA comparison, Graham number, and Dividend discount.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
25.7% below
+34.6% to fair value
ACCE score
55
out of 100
P/E
8.6x
forward 6.4x
1-year return
-11.9%
Dividend yield
0.00%
Genomma Lab Internacional in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Genomma Lab sells over-the-counter pharmaceuticals and personal care brands across Mexico, Latin America and the United States, including the Asepxia acne line, Tafirol analgesics and Ketoprofeno topical pain relievers. The case rests on a brand portfolio that sells without a prescription and carries pricing power in markets where branded self-care is still gaining share from informal and generic channels. We have no revenue growth, margin or return data in hand, so the thesis depends on valuation and balance sheet work we have not yet done. At 8.5x trailing and 7.2x forward earnings, the stock trades at a low multiple for a consumer health franchise with a market cap of 13.9B MXN, and the forward figure implies consensus expects earnings to rise. It warrants a deeper look to confirm whether the discount reflects weak fundamentals or a mispriced name with no index coverage.
⚠ Investor warnings · 1 flagAI-assisted·How I use AI
moderate
Revenue declining year over year
Revenue fell 6.0% year over year even though the 5-year revenue CAGR is +4.8%, so the top line has stalled recently. Earnings still grew 3.9%, which suggests cost or margin management is carrying the bottom line.
AI research notes
AI-assisted·How I use AIWritten Oct 24, 2026 · figures from 2026-10-23 · prices to Oct 23, 2026
Why it could do well
Free cash flow of MXN 2.0B over the last twelve months gives a 14.1% free cash flow yield at the current price.
The stock trades at a forward P/E of 6.4x against a sector median of 25.4x, a steep discount to peers.
Four of five valuation models in the consensus point to a fair value of MXN 20.64, which sits 25.7% above the share price.
Why it could disappoint
Revenue fell 6.0% year over year, and the stock's valuation rests on earnings that now face a difficult comparison.
Return on invested capital of 7.1% is thin, and the company has issued 3.5% more diluted shares in the last fiscal year.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where LABB.MX's valuation models land
Price
MXN 15.33
Model fair value
MXN 20.64
Model range
MXN 5.13 to MXN 39.35
Fair value MXN 20.64
Price MXN 15.33
The price sits inside the model range.
Model
Fair value
Upside
Discounted cash flow
Dividend discount
EV/EBITDA comparison
Graham number
P/E comparison
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores
+Score history: how each score moved over time
Analysts
Wall Street consensus
No analyst coverage yet.
Analyst intelligence INVESTOR FEATURE
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
+Price-target low / average / high vs the current price, with implied upside
+Forward revenue and EPS consensus by fiscal year
+ACCE fair-value models lined up against the Street
Smart Money
PRO
In one line
Trades are only made public after a delay. We show the delay so you know how old the news is.